A detailed history of Advisors Asset Management, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 11,451 shares of BMRN stock, worth $762,980. This represents 0.02% of its overall portfolio holdings.

Number of Shares
11,451
Previous 11,271 1.6%
Holding current value
$762,980
Previous $927,000 13.27%
% of portfolio
0.02%
Previous 0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$69.02 - $93.84 $12,423 - $16,891
180 Added 1.6%
11,451 $804,000
Q2 2024

Aug 14, 2024

BUY
$74.43 - $92.22 $66,168 - $81,983
889 Added 8.56%
11,271 $927,000
Q1 2024

May 14, 2024

BUY
$83.81 - $99.0 $103,924 - $122,760
1,240 Added 13.56%
10,382 $906,000
Q4 2023

Feb 14, 2024

SELL
$76.22 - $98.51 $28,887 - $37,335
-379 Reduced 3.98%
9,142 $881,000
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $93,874 - $108,624
1,083 Added 12.83%
9,521 $825,000
Q1 2023

May 12, 2023

BUY
$87.74 - $117.27 $101,690 - $135,915
1,159 Added 15.92%
8,438 $820,000
Q3 2022

Nov 08, 2022

SELL
$82.16 - $96.94 $47,242 - $55,740
-575 Reduced 59.46%
392 $33,000
Q2 2022

Aug 08, 2022

SELL
$71.48 - $86.85 $834,529 - $1.01 Million
-11,675 Reduced 92.35%
967 $80,000
Q1 2022

May 17, 2022

SELL
$74.28 - $92.69 $55,190 - $68,868
-743 Reduced 5.55%
12,642 $975,000
Q4 2021

Feb 15, 2022

SELL
$71.72 - $91.47 $18,790 - $23,965
-262 Reduced 1.92%
13,385 $1.18 Million
Q3 2021

Nov 12, 2021

SELL
$74.77 - $85.47 $444,283 - $507,862
-5,942 Reduced 30.33%
13,647 $1.06 Million
Q2 2021

Jul 30, 2021

SELL
$75.51 - $84.79 $9,514 - $10,683
-126 Reduced 0.64%
19,589 $1.64 Million
Q1 2021

May 07, 2021

SELL
$74.73 - $90.69 $123,902 - $150,364
-1,658 Reduced 7.76%
19,715 $1.49 Million
Q4 2020

Feb 12, 2021

BUY
$72.61 - $90.2 $281,218 - $349,344
3,873 Added 22.13%
21,373 $1.87 Million
Q3 2020

Nov 16, 2020

BUY
$71.87 - $131.03 $575,678 - $1.05 Million
8,010 Added 84.4%
17,500 $1.33 Million
Q2 2020

Aug 12, 2020

BUY
$79.55 - $124.22 $503,471 - $786,188
6,329 Added 200.22%
9,490 $1.17 Million
Q1 2020

May 15, 2020

BUY
$71.37 - $96.85 $4,068 - $5,520
57 Added 1.84%
3,161 $267,000
Q4 2019

Feb 14, 2020

SELL
$64.27 - $86.37 $6,619 - $8,896
-103 Reduced 3.21%
3,104 $262,000
Q3 2019

Nov 14, 2019

SELL
$67.4 - $85.11 $14,491 - $18,298
-215 Reduced 6.28%
3,207 $216,000
Q2 2019

Aug 14, 2019

SELL
$80.35 - $93.9 $10,766 - $12,582
-134 Reduced 3.77%
3,422 $293,000
Q1 2019

May 15, 2019

SELL
$84.2 - $98.62 $316,423 - $370,613
-3,758 Reduced 51.38%
3,556 $316,000
Q4 2018

Jan 31, 2019

SELL
$80.14 - $106.07 $210,046 - $278,009
-2,621 Reduced 26.38%
7,314 $623,000
Q3 2018

Nov 15, 2018

SELL
$93.92 - $105.72 $79,080 - $89,016
-842 Reduced 7.81%
9,935 $963,000
Q2 2018

Aug 15, 2018

SELL
$76.01 - $99.03 $338,396 - $440,881
-4,452 Reduced 29.23%
10,777 $1.02 Million
Q1 2018

May 15, 2018

SELL
$77.67 - $92.63 $39,456 - $47,056
-508 Reduced 3.23%
15,229 $1.24 Million
Q4 2017

Feb 13, 2018

SELL
$80.76 - $95.13 $37,795 - $44,520
-468 Reduced 2.89%
15,737 $1.4 Million
Q3 2017

Nov 07, 2017

BUY
$80.6 - $94.95 $1.31 Million - $1.54 Million
16,205
16,205 $1.51 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.